Theravance Biopharma (TBPH) AI Stock Analysis

• Market Cap: $898.42M
• Dividend Yield: N/A
• Average Volume (3M): 401.43K
• Price to Earnings (P/E): 31.5
• Beta (1Y): 0.95
• Revenue Growth: 27.12%
• EPS Growth: N/A
• Country: US
• Employees: 97
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 50,672,432
• 10 Day Avg. Volume: 614,204
• 30 Day Avg. Volume: 401,425
• PEG Ratio: -0.54
• Price to Book (P/B): 2.62
• Price to Sales (P/S): 7.14
• P/FCF Ratio: -38.73
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 5.89
• Enterprise Value/Gross Profit: 9.40
• Enterprise Value/Ebitda: -18.29
• 1Y Price Target: $25.60
• Price Target Upside: 44.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 1.8
• Revenue Forecast (FY): $107.28M

• Rating: 60 Neutral
• Price Target: $16.00 ▼(-9.76% Downside)

Theravance Biopharma's overall stock score reflects a mix of strong earnings call performance and technical momentum, offset by high valuation concerns and ongoing operational challenges. The company's strategic progress and financial discipline are positive, but investors should be cautious of the high P/E ratio and potential short-term technical pullbacks.

Positive Factors

Cash Position and Debt Management

A strong cash position with no debt enhances financial flexibility, allowing the company to invest in R&D and strategic initiatives without financial strain.

Revenue Growth and Milestones

Consistent revenue growth and milestone achievements indicate strong market demand and effective pricing strategies, supporting long-term financial health.

Strategic Partnerships

Strategic partnerships and milestone payments from Trelegy enhance revenue streams and demonstrate the value of collaborative efforts in expanding market reach.

Negative Factors

Operational Challenges

Operational challenges in trial execution can delay product development, impacting the timeline for bringing new therapies to market and potentially affecting revenue growth.

Negative EBIT and EBITDA Margins

Persistent negative margins suggest inefficiencies in operations, which could hinder profitability and require strategic adjustments to improve long-term financial performance.

Historical Equity Fluctuations

Volatility in equity levels can indicate financial instability, potentially affecting investor confidence and the company's ability to secure favorable financing terms.

Theravance Biopharma Business Overview & Revenue Model

Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

How the Company Makes Money

Theravance Biopharma generates revenue primarily through the commercialization of its pharmaceutical products. Key revenue streams include product sales from its approved therapies, such as the inhaled dual bronchodilator, YUPELRI (revefenacin), which is used for the treatment of chronic obstructive pulmonary disease (COPD). The company may also earn revenue through strategic partnerships and collaborations with other biopharmaceutical firms, where they may receive milestone payments, royalties on sales, and research funding. Additionally, Theravance could potentially benefit from licensing agreements that allow other companies to develop and market its products, further diversifying its revenue sources.

Theravance Biopharma Financial Statement Overview

Summary

Theravance Biopharma shows signs of financial recovery with improved profitability and cash flow management. However, negative EBIT and EBITDA margins indicate ongoing operational challenges. The balance sheet is stable with low leverage, but historical equity fluctuations pose potential risks.

Income Statement

Theravance Biopharma's income statement shows a mixed performance. The company has achieved a positive net profit margin of 16.88% in the TTM period, a significant improvement from previous losses. However, the EBIT and EBITDA margins remain negative, indicating ongoing operational challenges. Revenue growth is modest at 4.04%, suggesting a slow recovery. The gross profit margin is strong at 100% in the TTM, but historical volatility in profitability is a concern.

Balance Sheet

The balance sheet reflects moderate financial stability. The debt-to-equity ratio is low at 0.21, indicating manageable leverage. Return on equity has improved to 8.18% in the TTM, showing better utilization of equity. However, the equity ratio is not explicitly provided, and historical fluctuations in equity levels suggest potential risks.

Cash Flow

Theravance Biopharma's cash flow statement indicates strong cash flow management in the TTM period. The operating cash flow to net income ratio is robust at 4.48, and free cash flow to net income is nearly 1, showing efficient cash conversion. Despite a slight decline in free cash flow growth, the company has improved its cash flow position significantly compared to previous years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	80.33M	64.38M	57.42M	51.35M	55.31M	71.86M
Gross Profit	50.27M	64.38M	16.80M	-12.05M	-138.35M	71.86M
EBITDA	-25.84M	-38.45M	-51.65M	-76.08M	-232.83M	-287.82M
Net Income	29.34M	-56.42M	-55.19M	872.13M	-199.43M	-278.02M
Balance Sheet
Total Assets	415.46M	354.16M	382.00M	607.40M	374.82M	469.06M
Cash, Cash Equivalents and Short-Term Investments	329.68M	88.35M	102.43M	327.48M	173.47M	292.94M
Total Debt	33.68M	49.82M	49.16M	52.16M	669.52M	676.26M
Total Liabilities	182.78M	178.62M	169.00M	165.60M	713.39M	772.81M
Stockholders Equity	232.68M	175.54M	213.00M	441.80M	-338.57M	-303.75M
Cash Flow
Free Cash Flow	243.48M	-11.87M	-29.48M	-187.56M	-211.26M	-257.02M
Operating Cash Flow	243.70M	-11.54M	-27.00M	-186.99M	-207.86M	-250.40M
Investing Cash Flow	-90.19M	12.28M	-32.70M	1.15B	124.49M	10.72M
Financing Cash Flow	-2.12M	-2.50M	-198.93M	-758.81M	91.86M	263.08M

Theravance Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.73
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBPH, the sentiment is Positive. The current price of 17.73 is above the 20-day moving average (MA) of 15.77, above the 50-day MA of 14.81, and above the 200-day MA of 11.55, indicating a bullish trend. The MACD of 1.03 indicates Negative momentum. The RSI at 64.86 is Neutral, neither overbought nor oversold. The STOCH value of 80.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBPH.

Theravance Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$307.50M	―	-43.63%	―	―	-13.05%
TBPH	60 Neutral	$898.42M	31.52	14.03%	―	27.12%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DAWN	50 Neutral	$907.65M	―	-30.16%	―	31.11%	-46.75%
MRVI	49 Neutral	$894.97M	―	-41.06%	―	-30.56%	48.79%
NBTX	48 Neutral	$1.09B	―	―	―	―	―
TERN	45 Neutral	$2.30B	―	-29.12%	―	―	12.45%

Theravance Biopharma Corporate Events

Theravance Biopharma’s Earnings Call Highlights Robust Growth

Theravance Biopharma’s recent earnings call showcased a robust financial position, underscored by record sales and profitability for YUPELRI, significant advancements in ampreloxetine’s clinical trials, and anticipated milestones for Trelegy. Despite minor operational challenges, the company maintains a positive outlook, focusing on future growth and strategic objectives.

Theravance Biopharma Reports Strong Q3 2025 Results

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to treat respiratory diseases and other serious conditions, with a particular emphasis on therapies for chronic obstructive pulmonary disease (COPD) and neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA).

Theravance Completes Enrollment in Phase 3 CYPRESS Study

On August 25, 2025, Theravance Biopharma announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). This condition affects approximately 80% of MSA patients, leading to severe symptoms like dizziness and fainting. The study aims to address the unmet need for effective nOH treatments, with topline results expected in Q1 2026. If successful, ampreloxetine could become the first therapy to provide durable benefits for the estimated 40,000 U.S. patients with MSA-related nOH, potentially transforming treatment options in this underserved market.

The most recent analyst rating on (TBPH) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Theravance Biopharma Settles Patent Dispute with Cipla

On August 15, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Cipla to resolve ongoing patent litigation over YUPELRI® inhalation solution. The agreement allows Cipla to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by U.S. authorities, while litigation continues against Mankind Pharma Ltd.

The most recent analyst rating on (TBPH) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Theravance Biopharma’s Earnings Call Highlights Strategic Gains

Theravance Biopharma’s recent earnings call painted a picture of strong financial performance and strategic maneuvers, particularly with its key products YUPELRI and TRELEGY. The company showcased its momentum and financial strength, although some uncertainties linger regarding the YUPELRI launch in China and pending tax obligations.

Theravance Biopharma Reports Strong Q2 2025 Results

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory and neurological therapies, with a notable emphasis on its FDA-approved YUPELRI® for COPD and investigational drug ampreloxetine for neurogenic orthostatic hypotension in MSA patients.